Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
The microbiological studies investigated the activity of AR-2474 against a panel of bacteria known to cause topical infections, e.g., skin, eye etc. The study was performed on 100 clinical isolates with various resistance patterns. The panel included 21 MRSA, 27 coagulase-negative staphylococci (CNS), 24 group A streptococci (GAS) and 28 pneumococci. The compound exhibited potent activity against all of the isolates and this activity was unaffected by any pre-existing mechanism of resistance. Additionally, AR-2474 has been shown to be bactericidal and exhibit little or no propensity for the development of resistance.
The antibacterial activity and potency of AR-2474 was also confirmed in vivo against topical gold standard mupirocin (Bactroban®) in two distinct preclinical models of MRSA infection of the skin and MRSA nasal carriage. In both models, a preliminary topical formulation of AR-2474 was at least as efficacious as mupirocin.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.